

Senseera Biomed 2025 Abstract

- Executive Summary / Investment Rational

Senseera's chromatin liquid biopsy generates high-resolution gene expression and cell-state data from a simple blood draw, unlocking unprecedented molecular insights. This advancement creates major opportunities in diagnostics and drug development that are not accessible otherwise. Our initial focus is on a \$50B+ liver health diagnostics market, while we are collaborating with pharma to open new markets and reshape precision medicine.

- Core Technology

Senseera's platform applies cfChIP-seq to cell-free nucleosomes in blood, analyzing over 1M epigenomic features to generate genome-wide maps of gene activity and cell state with tissue-specific and cell-type resolution (Sadeh et al., Nature Biotechnology). This non-invasive approach unlocks molecular insights previously inaccessible—enabling breakthroughs in detection, monitoring, and biomarker discovery.

- Product Profile/Pipeline

Our pipeline has two pillars: liver disease diagnostics and pharma collaborations. We're advancing tests for transplant rejection, MASH risk, and early HCC detection, with strong clinical results driving our first expected launch in 2026. In parallel, we partner with pharma in areas like immunology and precision oncology, where cell-state insights can be game-changing.

- Business Strategy

Our platform delivers non-invasive gene expression and cell-state insights for diagnostics and drug development. We're initially targeting the broad liver disease market, with our liver transplant test expected to reach the market in 2026. Strategic pharma collaborations provide samples and data that fuel our database and AI engine—driving a feedback loop for product and market growth.

- What's Next?

We're expanding our clinical trials in MASH and HCC through collaborations with leading institutions. R&D will focus on enhancing performance through accelerated, AI-driven biomarker discovery. In 2026, we plan to launch U.S. operations, grow our commercial team, and advance our reimbursement strategy. Our strong team and unique platform position us to become leaders in precision diagnostics.